Scientists at the National Institutes of Health (NIH) have advanced research toward a potential treatment for alpha-gal syndrome (AGS), a tick-borne condition that causes individuals to develop an allergy to red meat. The discovery stems from a lab study exploring the use of antibodies, proteins that can target specific parts of the immune system.
AGS is an allergic reaction to alpha-gal, a sugar molecule found in the cells of most mammals but not humans. The condition is transmitted through the bite of certain ticks, most notably the lone star tick, which carries the alpha-gal molecule in its saliva. When a person is bitten, their immune system can become sensitized, leading to an allergic response upon consumption of red meat like beef, pork, or lamb. Symptoms can range from hives and nausea to severe stomach pain and, in critical cases, anaphylaxis. Some individuals may also react to dairy products.
Currently, there is no definitive treatment or cure for AGS. Prevention relies on avoiding tick bites and, for diagnosed individuals, strictly avoiding red meat and other trigger products. However, the NIH researchers found that laboratory-produced antibodies could bind to the immune system components responsible for triggering the allergic reaction, suggesting a possible pathway to prevent or mitigate AGS.
"Tick bite-associated cases of AGS are increasing in the US and globally, and there is currently no specific treatment or prevention for it," said Dr. John Powers, a director at the NIH. "This is a first step in potentially identifying ways to prevent [the condition] and develop new targeted therapies for people before they are affected."
The lone star tick, prevalent in the Northeast, Midwest, and South of the U.S., is primarily responsible for transmitting AGS. Their expanding geographic range, linked to increasing deer populations and warming temperatures, contributes to a rise in cases. Data from Virginia Commonwealth University indicates a significant increase in positive AGS tests between 2013 and 2024, though experts acknowledge that increased awareness may also play a role. The Centers for Disease Control and Prevention (CDC) estimates nearly 450,000 cases nationwide, with approximately 31 million people bitten by ticks annually.
Researchers noted that other allergies, such as those to pollen and peanuts, are already managed with antibody-based therapies, offering precedent for AGS. The initial focus of the NIH study was to explore whether alpha-gal-targeting antibodies could be effective against malaria, as the malaria parasite also contains the alpha-gal molecule. However, the antibodies showed little binding to the parasite.
Subsequently, the research team pivoted to investigate the antibodies' potential impact on AGS. Their findings indicated that 13 of the tested antibodies could bind to the immune system components that trigger AGS. Notably, one antibody demonstrated the ability to bind to an immune system cell that initiates the allergic reaction, suggesting it might help reduce the reaction's severity.
While the research is in its preliminary stages, scientists are hopeful that this discovery will pave the way for developing a treatment that could prevent allergic reactions in AGS sufferers, even if it does not cure the underlying condition. Dr. Peter Crompton, a senior investigator and lead author of the study, expressed enthusiasm for the research's contribution to advancing alpha-gal-specific antibodies as a potential intervention for AGS, highlighting it as an example of how global health research can yield significant breakthroughs.
For individuals already diagnosed with AGS, management of mild reactions typically involves standard allergy medications. Many patients also carry epinephrine auto-injectors for immediate relief in case of severe reactions. To avoid triggering an allergic response, sufferers must carefully check ingredient lists for hidden sources of alpha-gal, such as in stock cubes, gravy mixes, and gelatin-based products.